临床肿瘤学杂志
臨床腫瘤學雜誌
림상종류학잡지
CHINESE CLINICAL ONCOLOGY
2014年
5期
443-445
,共3页
马守东%胡万宁%孙国贵%李海丽
馬守東%鬍萬寧%孫國貴%李海麗
마수동%호만저%손국귀%리해려
紫杉醇%预处理方案%化学治疗
紫杉醇%預處理方案%化學治療
자삼순%예처리방안%화학치료
Paclitaxel%Premedication procedure%Chemotherapy
目的:观察含紫杉醇方案化疗时应用小剂量地塞米松预处理的效果及安全性,探索紫杉醇化疗预处理的新方案。方法151例患者应用紫杉醇联合铂类方案,紫杉醇135~175mg/m2,21天为1周期。依据输注紫杉醇前采用的两种不同地塞米松预处理方案,将151例患者分为标准组( n=75)和小剂量组( n=76),比较两组的不良反应。结果小剂量组与标准组的急性过敏发生率分别为8?0%、9?2%;外周神经毒性中周围神经炎发生率分别为38?7%、40?8%;肌肉关节痛发生率分别为52?0%、53?9%,两组不良反应差异均无统计学意义。结论紫杉醇化疗前应用小剂量地塞米松预处理与标准预处理方案合并急性过敏反应的发生率并无差异。
目的:觀察含紫杉醇方案化療時應用小劑量地塞米鬆預處理的效果及安全性,探索紫杉醇化療預處理的新方案。方法151例患者應用紫杉醇聯閤鉑類方案,紫杉醇135~175mg/m2,21天為1週期。依據輸註紫杉醇前採用的兩種不同地塞米鬆預處理方案,將151例患者分為標準組( n=75)和小劑量組( n=76),比較兩組的不良反應。結果小劑量組與標準組的急性過敏髮生率分彆為8?0%、9?2%;外週神經毒性中週圍神經炎髮生率分彆為38?7%、40?8%;肌肉關節痛髮生率分彆為52?0%、53?9%,兩組不良反應差異均無統計學意義。結論紫杉醇化療前應用小劑量地塞米鬆預處理與標準預處理方案閤併急性過敏反應的髮生率併無差異。
목적:관찰함자삼순방안화료시응용소제량지새미송예처리적효과급안전성,탐색자삼순화료예처리적신방안。방법151례환자응용자삼순연합박류방안,자삼순135~175mg/m2,21천위1주기。의거수주자삼순전채용적량충불동지새미송예처리방안,장151례환자분위표준조( n=75)화소제량조( n=76),비교량조적불량반응。결과소제량조여표준조적급성과민발생솔분별위8?0%、9?2%;외주신경독성중주위신경염발생솔분별위38?7%、40?8%;기육관절통발생솔분별위52?0%、53?9%,량조불량반응차이균무통계학의의。결론자삼순화료전응용소제량지새미송예처리여표준예처리방안합병급성과민반응적발생솔병무차이。
Objective To observe the safety and adverse reactions of the low-dose dexamethasone premedication with paclita-xel chemotherapy, explore a new paclitaxel premedication procedure. Methods Paclitaxel(135-175mg/m2) combined with platinum drugs was used in 151 patients, 21 days was a cycle. Two kinds of the premedication procedure be used before injection of paclitaxel, one in standard premedication procedure, the other in low-dose dexamethasone premedication procedure, observe the drug safety and adverse reactions. Results Paclitaxel chemotherapy in 75 cases of low-dose dexamethasone premedication and 76 cases of standards with acute allergy rates were 8?0% and 9?2%; peripheral neuritis rate were 38?7% and 40?8%, muscle and joint pain rate were 52?0%, 53?9%. There was no statistically significant between the two groups. Conclusion There was no difference in acute allergic reaction of paclitaxel chemotherapy before the application of Low-dose dexamethasone premedication compared with standards.